Replies to post #100115 on Biotech Values

[10nisman]

<< That's at least arguable. It's not simply the market share and pricing pressure if Teva gets approved too, it's the changed profit split with Novartis that is the driver in that scenario. >>

Understood. Under my model, MNTA is worth approximately $22 at the lower profit split (not factoring in non-Lovenox programs).

10nis